| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.lasalabs.com | |
| Market Cap | 192.59 Cr. | |
| Enterprise Value(EV) | 174.78 Cr. | 2022-03 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | -1.32 | Trailing Twelve Months Ending 2022-03 |
| Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2022-03 |
| Industry PE | 28.47 | Trailing Twelve Months Ending 2022-03 |
| Book Value / Share | 36.54 | Trailing Twelve Months Ending 2022-03 |
| Price to Book Value | 1.30 | Calculated using Price: 47.35 |
| Dividend Yield | 0.53 | Period Ending 2021-03 |
| No. of Shares Subscribed | 4.07 Cr. | 40,672,668 Shares |
| FaceValue | 10 | |
| Company Profile | ||
|
Lasa Supergenerics (Lasa) is a vertically integrated group spanning the entire veterinary, animal and human healthcare value chain-from discovery-to-delivery, with established credentials in research, manufacturing and global marketing. Lasa group is a veterinary API manufacturing entity, which was acquired in April 2012. The manufacturing base of Lasa group is located at Mahad, in the Konkan region of Maharashtra. It specialises in ‘catalyst chemistry’ and manufactures anthelmintic/ veterinary API products with the largest production capabilities and product categories in India. To efficiently control the supply chain, the group backward integrated its key molecules-from discovery research up to full-scale bulk production. Lasa group’s marketing footprint is entrenched across developing markets in multiple countries. Similarly, the group expects to augment its export footprint significantly in width and depth in the future. The group has alliances with leading Indian and global animal health care conglomerates, and uses Good Manufacturing Practice (GMP) and world-class technologies in its operations. Business area of the company The company is specialises in ‘catalyst chemistry’ and manufactures anthelmintic/ veterinary API products with the largest production capabilities and product categories in India Product Categories
|
||
Company Profile
Lasa Supergenerics (Lasa) is a vertically integrated group spanning the entire veterinary, animal and human healthcare value chain-from discovery-to-delivery, with established credentials in research, manufacturing and global marketing. Lasa group is a veterinary API manufacturing entity, which was acquired in April 2012. The manufacturing base of Lasa group is located at Mahad, in the Konkan region of Maharashtra. It specialises in ‘catalyst chemistry’ and manufactures anthelmintic/ veterinary API products with the largest production capabilities and product categories in India. To efficiently control the supply chain, the group backward integrated its key molecules-from discovery research up to full-scale bulk production.
Lasa group’s marketing footprint is entrenched across developing markets in multiple countries. Similarly, the group expects to augment its export footprint significantly in width and depth in the future. The group has alliances with leading Indian and global animal health care conglomerates, and uses Good Manufacturing Practice (GMP) and world-class technologies in its operations.
Business area of the company
The company is specialises in ‘catalyst chemistry’ and manufactures anthelmintic/ veterinary API products with the largest production capabilities and product categories in India
Product Categories
| 1 Day |
|
+2.74% |
| 1 Week |
|
+4.73% |
| 1 Month |
|
-17.39% |
| 3 Month |
|
-2.50% |
| 6 Month |
|
-20.36% |
| 1 Year |
|
-37.84% |
| 2 Year |
|
+53.39% |
| 5 Year |
|
|
| 10 Year |
|
| 6 years | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | |
| Return on Equity (%) | 8.65 | 14.33 | -10.81 | 2.94 | 15.17 | ||
| Return on Capital Employed (%) | 14.45 | 12.80 | -3.73 | 6.77 | 17.14 | ||
| Return on Assets (%) | 2.07 | 4.79 | -4.44 | 1.50 | 10.43 |
| Particulars | 7 years | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03* Rs. Cr. |
| Shh. Funds | 0 | 75 | 117 | 105 | 141 | 159 | 149 | |
| Non Curr. Liab. | 0 | 83 | 62 | 43 | 11 | 8 | 7 | |
| Curr. Liab. | 70 | 107 | 107 | 76 | 41 | 44 | ||
| Minority Int. | ||||||||
| Equity & Liab. | 0 | 228 | 287 | 255 | 229 | 208 | 199 | |
| Non Curr. Assets | 149 | 178 | 170 | 153 | 144 | 127 | ||
| Curr. Assets | 0 | 79 | 109 | 86 | 76 | 64 | 72 | |
| Misc. Exp. not W/O | 0 | |||||||
| Total Assets | 0 | 228 | 287 | 255 | 229 | 208 | 199 |
| Particulars | 7 years | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. TTM |
| Net Sales | 199 | 244 | 170 | 167 | 202 | 137 | ||
| Other Income | 2 | 3 | 1 | 0 | 0 | 0 | ||
| Total Income | 201 | 247 | 170 | 167 | 203 | 137 | ||
| Total Expenditure | -153 | -202 | -159 | -137 | -155 | -121 | ||
| PBIDT | 48 | 45 | 12 | 30 | 47 | 16 | ||
| Interest | -12 | -11 | -8 | -8 | -2 | 0 | ||
| Depreciation | -8 | -18 | -19 | -17 | -16 | -14 | ||
| Taxation | 0 | -3 | 4 | -1 | -7 | 1 | ||
| Exceptional Items | -26 | -8 | ||||||
| PAT | 2 | 12 | -12 | 4 | 23 | -5 | ||
| Adjusted EPS | 472 | 5 | -5 | 1 | 6 | -1 |
| Particulars | 6 years | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Cash Fr. Operatn. | 0 | -3 | 40 | 41 | 14 | 41 | |
| Cash Fr. Inv. | 0 | -44 | -7 | -2 | -4 | ||
| Cash Fr. Finan. | 0 | 0 | 4 | -33 | -10 | -36 | |
| Net Change | 0 | -3 | 0 | 0 | 2 | 1 | |
| Cash & Cash Eqvt | 0 | 0 | 1 | 0 | 3 | 4 |
|
Wed, 27 Apr 2022
Press Release
|
|
|
Tue, 26 Apr 2022
Press Release
|
|
|
Tue, 26 Apr 2022
Related Party Transaction
|
| Thu, 19 May 2022 |
Opening at High
|
Closing Below Previous Low
|
High Decrease 1 Month
|
High Decrease 6 Months
|
High Decrease 1 Year
|
Equities
M.F.
Sectors